Adotevi N, Lewczuk E, Sun H, Joshi S, Dabrowska N, Shan S, Williamson J, Kapur J (2020) α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor plasticity sustains severe, fatal status epilepticus. Ann Neurol 87(1):84–96

CAS  PubMed  Google Scholar 

Ali H, Naim M, Senum SR, AlSahow A, Bahbahani Y, Abu-Farha M, Abubaker J, Mohammad A, Al-Hunayan A, Asbeutah AM, Zayed M, Devarajan S, Hussain N, John SE, Channanath A, Thanaraj TA, Al-Ali M, AlMousawi M, Al-Mulla F, Harris PC (2022) The genetic landscape of autosomal dominant polycystic kidney disease in Kuwait. Clin Kidney J 16(2):355–366. https://doi.org/10.1093/ckj/sfac236

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR (2022) Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Life Sci 303:120675. https://doi.org/10.1016/j.lfs.2022.120675

Article  CAS  PubMed  Google Scholar 

Amin S, Sangadi I, Allman-Farinelli M, Badve SV, Boudville N, Coolican H, Coulshed S, Foster S, Fernando M, Haloob I, Harris DC (2023) Participant perceptions in a long-term clinical trial of autosomal dominant polycystic kidney disease. Kidney Med 5(9):100691. https://doi.org/10.1016/j.xkme.2023.100691

Article  PubMed  PubMed Central  Google Scholar 

Angulo J, El Assar M, Sevilleja-Ortiz A, Sánchez-Ferrer A, Romero-Otero J, Martínez-Salamanca JI, La Fuente JM, Rodríguez-Mañas L (2019) Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention. Redox Biol 26:101271. https://doi.org/10.1016/j.redox.2019.101271

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aukema HM (2021) Prostaglandins as potential targets for the treatment of polycystic kidney disease. Prostaglandins Leukot Essent Fatty Acids 164:102220. https://doi.org/10.1016/j.plefa.2020.102220

Article  CAS  PubMed  Google Scholar 

Badoiu SC, Greabu M, Miricescu D, Stanescu-Spinu II, Ilinca R, Balan DG, Balcangiu-Stroescu AE, Mihai DA, Vacaroiu IA, Stefani C, Jinga V (2023) PI3K/AKT/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL/HIF axis. Int J Mol Sci 24(9):8391. https://doi.org/10.3390/ijms24098391

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith EL III, Zhou X, Matsui KO, Wu PC, Sankaridurg P, Chia A, Rosman M (2020) Myopia. Nat Rev Disease Primers 6(1):99. https://doi.org/10.1128/mcb.00099-20

Article  CAS  PubMed  Google Scholar 

Baird L, Yamamoto M (2020) The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol Cell Biol 40(13):e00099-20. https://doi.org/10.1128/MCB.00099-20

Article  PubMed  PubMed Central  Google Scholar 

Baroni D, Scarano N, Ludovico A, Brandas C, Parodi A, Lunaccio D, Fossa P, Moran O, Cichero E, Millo E (2023) In silico and in vitro evaluation of the mechanism of action of three VX809-based hybrid derivatives as correctors of the f508del cftr protein. Pharmaceuticals 16(12):1702. https://doi.org/10.3390/ph16121702

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG (2002) PKD1 induces p21waf1 and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109(2):157–168. https://doi.org/10.1016/s0092-8674(02)00716-x

Article  CAS  PubMed  Google Scholar 

Braccia C, Christopher JA, Crook OM, Breckels LM, Queiroz RM, Liessi N, Tomati V, Capurro V, Bandiera T, Baldassari S, Pedemonte N (2022) CFTR rescue by Lumacaftor (VX-809) induces an extensive reorganization of mitochondria in the cystic fibrosis bronchial epithelium. Cells 11(12):1938. https://doi.org/10.3390/cells11121938

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brovkina AS, Ushakov RE, Vassilieva IO, Domnina AP, Burova EB (2022) Involvement of the PI3K/Akt/mTOR pathway in controlling chondrogenic differentiation of endometrial mesenchymal stromal cells. Cell Tissue Biol 16(Apr):130–139. https://doi.org/10.1134/S1990519X22020031

Article  CAS  Google Scholar 

Cao X, Wang P, Yuan H, Zhang H, He Y, Fu K, Fang Q, Liu H, Su L, Yin L, Xu P (2022) Benzodiazepine derivatives as potent vasopressin V2 receptor antagonists for the treatment of autosomal dominant kidney disease. J Med Chem 65(13):9295–9311

CAS  PubMed  Google Scholar 

Celentano S, Capolongo G, Pollastro R (2019) Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?. Giornale Italiano Nefrol Organo Ufficiale Della Soc Italiana Nefrol, 36(5)

Chang MY, Hsu SH, Ma LY, Chou LF, Hung CC, Tian YC, Yang CW (2022) Effects of suramin on polycystic kidney disease in a mouse model of polycystin-1 deficiency. Int J Mol Sci 23(15):8499. https://doi.org/10.3390/ijms23158499

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen MY, Hsu CH, Setiawan SA, Tzeng DT, Ma HP, Ong JR, Chu YC, Hsieh MS, Wu AT, Tzeng YM, Yeh CT (2023) Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis. Phytomedicine 108:154478. https://doi.org/10.1016/j.phymed.2022.154478

Article  CAS  PubMed  Google Scholar 

Costa I, Barbosa DJ, Benfeito S, Silva V, Chavarria D, Borges F, Remião F, Silva R (2023) Molecular mechanisms of ferroptosis and their involvement in brain diseases. Pharmacol Ther 244:108373. https://doi.org/10.1016/j.pharmthera.2023.108373

Article  CAS  PubMed  Google Scholar 

Cruz NM, Freedman BS (2018) CRISPR gene editing in the kidney. Am J Kidney Dis 71(6):874–883

CAS  PubMed  PubMed Central  Google Scholar 

Dagorn PG, Buchholz B, Kraus A, Batchuluun B, Bange H, Blockken L, Steinberg GR, Moller DE, Hallakou-Bozec S (2023) A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease. Kidney Int 103(5):917–929. https://doi.org/10.1016/j.kint.2023.01.026

Article  CAS  PubMed  Google Scholar 

Della Sala A, Prono G, Hirsch E, Ghigo A (2021) Role of protein kinase A-mediated phosphorylation in CFTR channel activity regulation. Front Physiol 12:690247

PubMed  PubMed Central  Google Scholar 

Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, Valenti G (2019) Lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells. Int J Mol Sci 21(1):183

PubMed  PubMed Central  Google Scholar 

Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G (2021) Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J. https://doi.org/10.1096/fj.202100774R

Article  PubMed  Google Scholar 

Fan LX, Li X, Magenheimer B, Calvet JP, Li X (2012) Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int 81(1):76–85. https://doi.org/10.1038/ki.2011.296

Article  CAS  PubMed  Google Scholar 

Fibbi B, Marroncini G, Naldi L, Anceschi C, Errico A, Norello D, Peri A (2023) Hyponatremia and cancer: from bedside to benchside. Cancers 15(4):1197

CAS  PubMed  PubMed Central  Google Scholar 

Gareev I, Ahmad A, Wang J, Beilerli A, Ilyasova T, Sufianov A, Beylerli O (2023) Gastric juice non-coding RNAs as potential biomarkers for gastric cancer. Front Physiol 14:1179582. https://doi.org/10.3389/fphys.2023.1179582

Article  PubMed  PubMed Central  Google Scholar 

González F, Mather KJ, Considine RV, Abdelhadi OA, Acton AJ (2020) Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome. Am J Physiol Endocrinol Metab 319(4):E744–E752

PubMed  PubMed Central  Google Scholar 

Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J (2017) microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun 8(1):1–5

Google Scholar 

Hallows KR, Abebe KZ, Li H, Saitta B, Althouse AD, Bae KT, Lalama CM, Miskulin DC, Perrone RD, Seliger SL, Watnick TJ (2023) Association of longitudinal urinary metabolic biomarkers with ADPKD severity and response to metformin in TAME-PKD clinical trial participants. Kidney Int Rep 8(3):467–477. https://doi.org/10.1016/j.ekir.2022.11.019

Article